ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,924 companies indexed · Last updated: today
DirectoryFinance & InsuranceHolding CompaniesZurichVeraxa Biotech AG
Veraxa Biotech AG Logo
Verified· 3 sources

Veraxa Biotech AG

Summary

About the company

Veraxa Biotech Holding AG develops antibody-based cancer therapeutics, including antibody–drug conjugates (ADCs) and BiTAC bispecific formats, and employs proprietary technologies such as droplet‑based functional antibody screening, genetic code expansion for positional conjugation, and bioorthogonal click chemistry. The company is advancing a proprietary oncology pipeline that includes ADC and BiTAC TCE programs, with the VX‑A901 program in clinical studies for AML.

AI-generated
Offering

Products & services

Industry:Holding Companies
✓ Offered6
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
BiTAC TCEs
Bi-targeted T-cell-engaging bispecific molecules with two complementary antibody precursors; CD3 binding is activated only upon co-localisation on tumour cells to reduce off-tumour toxicity.
ADC technologies
Antibody-drug-conjugate technologies with genetically precise conjugation-site positioning, efficient click chemistry and proprietary payloads for homogeneous, stable ADCs with improved pharmacokinetics.
Functional antibody screening
High-throughput droplet microfluidics with single-cell analysis to identify functional antibodies against various targets, including internalising as well as agonistic and antagonistic antibodies.
BiTAC platform
Antibody platform with two complementary precursors that only form the therapeutically active molecule upon simultaneous target binding on cancer cells, enabling selective activation.
Pipeline of novel antibody-based cancer therapeutics
Development of a clinical pipeline of novel oncology programmes, in particular BiTAC-TCEs, BsADCs, BiTAC-ADCs and monoclonal antibodies for AML, breast, lung, colon and pancreatic cancer.
Press

Media

July 1, 2026Media
Einschätzung: Erster Börsengang einer Beteiligung dürfte Xlife kräftig Schub geben
fuw.ch
Comparisons

Veraxa Biotech AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Veraxa Biotech AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Veraxa Biotech AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Talacker 35
8001 Zurich

At a glance

Legal form
Corporation
UID
CHE-441.201.868
Founded
2025 · 1 year
Last commercial register change
July 30, 2026
Employees
1 to 10

Knowledge

No knowledge articles yet

Once Veraxa Biotech AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

UA
Under Armour Global CH GmbH
Zurich
PD
Pensionsstiftung der Stiftung Zürcher Blutspendedienst SRK
Zurich
NH
Neurimmune Holding AG
Schlieren
AH
Angst Holding AG
Zurich
TA
Tectus AG
Zurich
BH
Brust-Zentrum Holding AG
Zurich
UH
u-blox Holding AG
Thalwil
EZ
ETH Zürich SEC AG
Zürich Eth-Zentrum